1.Effects of alizarin on gut microbiota structure and the ILC3/IL-22/GDNF pathway in a mouse model of colorectal cancer
Liu Ruia ; Zhou Taob ; Zhao Liqunc ; Li Wanyuana
Chinese Journal of Cancer Biotherapy 2026;33(10):1070-1077
[摘 要] 目的:探讨茜草素对结直肠癌(CRC)小鼠模型肠道菌群结构及3型固有淋巴样细胞/白细胞介素22/胶质细胞源性神经营养因子(ILC3/IL-22/GDNF)相关指标的影响。方法:将40只BALB/c小鼠随机分为对照组、模型组、低剂量茜草素组、高剂量茜草素组和美沙拉秦组,每组8只。采用1,2-二甲基肼(DMH)联合葡聚糖硫酸钠(DSS)诱导构建CRC小鼠模型。检测各组小鼠结肠长度、结肠指数、肿瘤负荷及肿瘤体积;采用H-E染色观察结肠组织病理变化;采用16S rRNA高通量测序分析肠道菌群组成及多样性;采用流式细胞术检测结肠组织IL-22⁺ILC3细胞比例;采用ELISA检测结肠组织IL-22水平;采用Western blotting法检测结肠组织GDNF蛋白表达水平。结果:与对照组相比,模型组小鼠的结肠长度及Chao1、Sobs、ACE、Shannon和Simpson指数显著降低(P < 0.05),结肠指数、IL-22⁺ILC3细胞比例、IL-22水平和GDNF蛋白表达水平显著升高(P < 0.05)。与模型组相比,低、高剂量茜草素组小鼠的结肠长度及上述5项α多样性指数显著升高(P < 0.05),结肠指数、肿瘤负荷、肿瘤体积、IL-22⁺ILC3细胞比例、IL-22水平和GDNF蛋白表达水平显著降低(P < 0.05)。此外,茜草素干预可改变CRC模型小鼠肠道菌群组成,提高厚壁菌门、阿克曼菌科、毛螺菌科、瘤胃球菌属和双歧杆菌属等菌群相对丰度,降低拟杆菌门、梭杆菌门、肠球菌科、肠球菌属及梭杆菌属等菌群相对丰度(P < 0.05)。结论:茜草素可改善DMH/DSS诱导CRC小鼠的肠道菌群结构,调节肠道免疫微环境,其抗CRC作用可能与ILC3/IL-22/GDNF相关指标变化有关。
2.Expression and characterization of ENO1 protein and its associated active site deletion mutant proteins in a baculovirus expression vector system
DAI Pengyua ; YANG Ruia ; ZHANG Tingtinga ; MA Xinyuna ; LIU Huilingb
Chinese Journal of Cancer Biotherapy 2024;31(7):669-674
[摘 要] 目的:利用昆虫杆状病毒表达系统(昆虫BEVS)表达糖酵解酶α-烯醇化酶(ENO1)及其3种酶活性位点缺失突变的ENO1蛋白ENO1-M1、ENO1-M2和ENO1-M3,为后续宫颈癌的代谢治疗研究奠定基础。方法:利用分子克隆技术将优化后ENO1序列插入pFastBacTM1载体,获得含有目的基因的重组质粒pFastBac-ENO1。分别缺失ENO1发挥糖酵解酶功能的3个活性位点,进行优化后将其插入pFastBacTM1载体,获得3个活性位点缺失的重组质粒pFastBac-M1、pFastBac-M2和pFastBac-M3。通过转座、转染后获得重组杆状病毒rBV-ENO1、rBV-M1、rBV-M2和rBV-M3,利用WB法对目的蛋白的表达及特异性进行检测。结果:成功扩增重组杆粒rBacmid-ENO1、rBacmid-M1、rBacmid-M2和rBacmid-M3,获得大小约2 000 bp的基因片段,与预期大小相符。昆虫BEVS可表达ENO1蛋白及其3个酶活位点缺失的重组蛋白ENO1-M1、ENO1-M2和ENO1-M3,其分子量约为52 000,与预期相符。WB法鉴定这些蛋白能与特异性标签His-tag发生反应。结论:通过昆虫BEVS成功表达目的蛋白ENO1及其酶活性位点缺失蛋白ENO1-M1、ENO1-M2和ENO1-M3,这些蛋白具有反应原性,为后续测定这些蛋白与ENO1单抗亲和力创造了条件。
3.Dynamic changes of HBsAg and hepatitis B virus DNA in chronic hepatitis B patients with entecavir monotherapy for 5 years
Fengpinga WU ; Miaoxianb LI ; Yikaia WANG ; Ruia LU ; Yixina LIU ; Shuangsuoa DANG
Journal of Clinical Hepatology 2021;37(5):1047-1052.
ObjectiveTo investigate the dynamic changes of serum HBsAg and hepatitis B virus (HBV) DNA in chronic hepatitis B patients (CHB) with entecavir (ETV) monotherapy for 5 years. MethodsA retrospective analysis was performed for the clinical data of 918 CHB patients who attended the Second Affiliated Hospital of Xi’an Jiaotong University from January 2012 to August 2020 and received ETV monotherapy for ≥5 years, among whom 556 had positive HBeAg and 362 had negative HBeAg at initial treatment. Serum HBsAg level and HBV DNA load at baseline and at 1, 2, 3, 4, and 5 years of treatment were collected to analyze their dynamic changes. The t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; log10 logarithmic transformation was performed for non-normally distributed repeated measurement data, and then a repeated-measures analysis of variance was used for comparison between groups or within each group; the chi-square test was used for comparison of categorical data between two groups. ResultsBoth HBeAg-positive and HBeAg-negative patients had a significant reduction in HBsAg level over the time of ETV treatment (F=174.168 and 49.845, both P<0.001). The HBeAg-positive patients had a baseline HBsAg level of 18 043.1 (7868.9-26 342.4) IU/ml, which significantly decreased to 13976 (626.4-3419.4) IU/ml after 5 years of ETV treatment (P<0.001); the HBeAg-positive patients had a baseline HBV DNA load of (67±1.7) log10 IU/ml and achieved an HBV DNA clearance rate of 100% after 5 years of ETV treatment. The HBeAg-negative patients had a baseline HBsAg level of 2420.0 (662.6-5621.2) IU/ml, which significantly decreased to 407.2 (56.7-1104.7) IU/ml after 5 years of ETV treatment (P<0.001); the HBeAg-negative patients had a baseline HBV DNA load of 4.9±1.4 log10 IU/ml and achieved an HBV DNA clearance rate of 100% after 5 years of ETV treatment. The HBeAg-positive patients had a significantly higher median HBsAg level than the HBeAg-negative patients at each time point (all P<0.001). Both HBeAg-positive and HBeAg-negative patients showed a changing trend of rapid reduction followed by slow reduction in HBsAg, and the mean annual rate of reduction in HBsAg in the first 2 years of ETV treatment was significantly higher than that in the last 3 years of ETV treatment (HBeAg-positive: Z=-13.605, P<0001; HBeAg-negative: Z=-5.950, P<0.001). The HBeAg-positive patients had a significantly lower HBV DNA clearance rate than the HBeAg-negative patients at 1 year of ETV treatment (χ2=71.013, P<0.001), and both HBeAg-positive and HBeAg-negative patients achieved an HBV DNA clearance rate of 100% at 2, 3, 4, and 5 years of treatment. After 5 years of ETV treatment, the cumulative proportions of patients with HBsAg clearance, HBsAg <200 IU/ml, HBsAg <1000 IU/ml, and HBsAg<1500 IU/ml were 3.6%, 23.9%, 57.0%, and 67.3%, respectively. ConclusionDuring the EVT treatment of CHB, the levels of HBsAg and HBV DNA gradually decrease, and the level of HBsAg shows a trend of rapid reduction followed by slow reduction. After 5 years of ETV monotherapy, 67.3% of the patients can achieve an HBsAg level of <1500 IU/ml.

Result Analysis
Print
Save
E-mail